Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000963 Huadong Medicine Co.,Ltd.

Closed 04-30 15:00:00

33.35

-0.19

-0.57%

High33.59	Low33.20	Vol13.22M
Open33.52	D1 Closing33.54	Amplitude1.16%
Mkt Cap58.50B	Tradable Cap58.46B	Total Shares1.75B
T/O441.00M	T/O Rate0.75%	Tradable Shares1.75B
P/B2.29	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":33.35,"timestamp":1777532580000,"preClose":33.54,"halted":0,"volume":13215462,"delay":0,"changeRate":-0.0057,"floatShares":1753000000,"shares":1754000000,"eps":1.9968,"marketStatus":"Closed","change":-0.19,"latestTime":"04-30 15:00:00","open":33.52,"high":33.59,"low":33.2,"amount":441000000,"amplitude":0.0116,"askPrice":33.36,"askSize":114,"bidPrice":33.35,"bidSize":209,"shortable":0,"etf":0,"ttmEps":1.9968,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":33.54,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":36.89,"lowLimit":30.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":2.29,"roa":"--","peRate":16.701723,"roe":"3.97%","epsLYR":1.9484,"committee":0.120567,"marketValue":58487000000,"turnoverRate":0.0075,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-05-06.","floatMarketCap":58463000000},"requestUrl":"/m/hq/s/000963/tweets","defaultTab":"tweets","newsList":[{"id":"2629183058","title":"Huadong Medicine's Attributable Profit Slips 2.8% in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2629183058","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629183058?lang=en_us&edition=fundamental","pubTime":"2026-04-24 15:03","pubTimestamp":1777014197,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) attributable profit fell 2.8% year over year to 3.41 billion yuan in 2025, according to a Friday filing with the Shanghai bourse.Operating revenue jumped 4.1% year over year to 43.6 billion yuan.Shares increased 3% during afternoon trading on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0132","BK0209","BK0175","BK0196","LU1969619763.USD","BK0188","BK0183","BK0187","000963","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894454","title":"Huadong Medicine Registers New Aesthetics Product Variant in China; Shares Jump 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894454","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629894454?lang=en_us&edition=fundamental","pubTime":"2026-04-24 13:25","pubTimestamp":1777008337,"startTime":"0","endTime":"0","summary":"Huadong Medicine  has obtained a medical device registration certificate from China's National Medical Products Administration for a new variant of its Ellansé aesthetics product, according to a Shenzhen Stock Exchange filing on Friday.The newly approved Ellansé M-type is a Class III medical device for injection containing polycaprolactone microspheres for facial filling. It has been approved for market launch, said Huadong.The M-type variant is designed for the temporal region. Huadong has already been marketing its Ellansé S-type product in China since August 2021.Shares of the company rose 4% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0196","BK0187","BK0132","BK0209","BK0175","LU2328871848.SGD","BK0188","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839123","title":"BRIEF-Huadong Medicine 2025 Net Profit Down 2.8% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839123","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629839123?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:07","pubTimestamp":1776946028,"startTime":"0","endTime":"0","summary":"BRIEF-Huadong Medicine 2025 Net Profit Down 2.8% Y/YApril 23 (Reuters) - Huadong Medicine Co Ltd 000963.SZ:SAYS Q1 NET PROFIT UP 9.6% Y/Y2025 NET PROFIT DOWN 2.8% Y/YSource textSource text 2Further company coverage: 000963.SZ (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL4N4161GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0132","BK0175","BK0209","BK0196","BK0187","000963","BK0183","LU1969619763.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627402812","title":"Huadong Medicine's Weight-Loss Drug Marketing Application Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2627402812","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627402812?lang=en_us&edition=fundamental","pubTime":"2026-04-15 16:34","pubTimestamp":1776242065,"startTime":"0","endTime":"0","summary":"Huadong Medicine  said China's drug administrator accepted its marketing application for semaglutide injection.The drug is used for long-term weight management in obese or overweight adults, according to a Wednesday filing with the Shenzhen bourse.Shares of the drugmaker closed 2% higher Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0188","000963","BK0209","BK0196","BK0183","LU1969619763.USD","BK0132","LU2328871848.SGD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118117","title":"CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118117?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:07","pubTimestamp":1775826431,"startTime":"0","endTime":"0","summary":"CARsgen annual report for 2025 flagged a shift into value realization, led by stronger commercialization of BCMA CAR-T zevorcabtagene autoleucel.Huadong Medicine placed 218 confirmed orders for zevor-cel during 2025.Claudin18.2 CAR-T satricabtagene autoleucel entered China NDA review in June 2025, with approval expected in first half of 2026.Strategy pivot accelerated toward off-the-shelf allogeneic CAR-T, with CT0596 and CT1190B positioned for IND clearance and Phase Ib trial starts in 2026 in China.Manufacturing footprint expanded in Shanghai, with a new Jinshan commercial base planned under a project capped at RMB 370 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDLch6MLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000963","BK0188","BK1585","BK0132","BK0187","BK0175","LU2328871848.SGD","BK1161","BK1587","BK1574","BK0209","02171","BK0183","LU1969619763.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178382932","title":"Global First Recombinant Botulinum Toxin Type A Approved, Huadong Medicine Ushers in New Era","url":"https://stock-news.laohu8.com/highlight/detail?id=1178382932","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178382932?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:46","pubTimestamp":1774615613,"startTime":"0","endTime":"0","summary":"On March 27, 2026, Huadong Medicine Co.,Ltd. announced the approval of a new drug. According to the announcement, an injectable recombinant botulinum toxin type A (R&D code: YY001, brand name:...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","LU1969619763.USD","BK0187","LU2328871848.SGD","BK0188","150259","BK0209","000963","BK0196","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622456008","title":"China Stocks Jump on Positive Industrial Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622456008","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622456008?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:41","pubTimestamp":1774597261,"startTime":"0","endTime":"0","summary":"Chinese equities made gains at the close of the trading week as sentiment was uplifted over the growth of domestic industrial profits.The Shanghai Composite Index added 0.6%, or 24.64 points, to cap Friday's trade at 3,913.72. The Shenzhen Component Index jumped 1.1%, or 153.93 points, to 13,760.37.The profits of China's industrial enterprises jumped 15.2% year on year to 1.024 trillion yuan in January and February, according to the National Bureau of Statistics, despite the risks brought by the ongoing Middle East conflict.Among industries, profits of the computer manufacturing industry rose two-fold from a year earlier, while those of the non-ferrous metal industry grew 1.5-fold.In corporate news, Hubei Dinglong  skyrocketed 17.3% after its 2025 attributable net profit climbed 38% year on year to 720.2 million yuan.Wuxi Chemical Equipment  rose 3.3% after passing Saudi Aramco's supplier qualification certification for two products.Huadong Medicine  jumped 5.9% after its unit, Sino-Am","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0188","000963","BK0209","BK0070","BK0196","BK0183","BK0251","LU1969619763.USD","BK0229","BK0132","BK0138","001332","LU2328871848.SGD","300054","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622843425","title":"Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622843425","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622843425?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:25","pubTimestamp":1774596353,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Sino-American East China, received approval from China's National Medical Products Administration for the clinical trial of HDM2024 for injection, according to a Shenzhen bourse filing on Friday.The drug will be tested for advanced solid tumors.The Chinese drugmaker's shares soared 6% at the close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0175","BK0132","LU1969619763.USD","BK0187","BK0209","000963","BK0188","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109379648","title":"Huadong Medicine Subsidiary Gets Nod for HDM2024 Injection Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1109379648","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109379648?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:35","pubTimestamp":1774517701,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received a drug clinical trial approval notice from the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","LU2328871848.SGD","000963","BK0196","BK0188","BK0175","LU1969619763.USD","BK0183","BK0209","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618909714","title":"Huadong Medicine Unit Gets US FDA's Nod to Trial Advanced Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2618909714","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618909714?lang=en_us&edition=fundamental","pubTime":"2026-03-12 11:37","pubTimestamp":1773286635,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Hangzhou Sino-American Huadong Pharmaceutical, received approval from the U.S. Food and Drug Administration for the clinical trial of injectable HDM2024, according to a Thursday disclosure on the Shenzhen bourse.The Chinese drugmaker will conduct phase I clinical trials to test the drug as a treatment for advanced solid tumors in the U.S.The company's shares slipped over 1% during the morning trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK0187","LU1969619763.USD","LABU","BK4588","BK0196","000963","LU2328871848.SGD","BK0183","LU1815336091.USD","BK0188","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD","BK0175","BK4157","BK0132","LU0757428866.USD","AEIS","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165877473","title":"Huadong Medicine's Investigational Drug HDM2024 Receives FDA Clearance for US Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1165877473","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165877473?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:46","pubTimestamp":1773229589,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co., Ltd. (000963.SZ) announced that on March 10, 2026, its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received notification from the U.S. Food and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","BK4588","LABU","LU1969619763.USD","BK0187","LU2328871848.SGD","BK0188","BK0209","000963","BK0196","BK4585","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108655208","title":"Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=1108655208","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108655208?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:28","pubTimestamp":1772807329,"startTime":"0","endTime":"0","summary":"The global weight-loss drug market is entering a new phase, driven by the launch of oral formulations, upcoming generic competition, and price reductions in the United States for blockbuster products...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","HK0000165453.HKD","LU1023059063.AUD","LU1066053197.SGD","AZN","LU0985481810.HKD","BK4592","BK4588","SG9999003800.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK1583","LU0234572021.USD","LU2488822045.USD","LU0321505439.SGD","LU1057294990.SGD","LLY","BK4533","LU0289739699.SGD","LU0122379950.USD","NVO","LU0868494617.USD","BK4534","BK4581","PFE","SGXZ57979304.SGD","BK4585","LU0225284248.USD","LU0502904849.HKD","LU2097828557.USD","MRK","SG9999002232.USD","LU2328871848.SGD","LU2097828474.EUR","LU0321505868.SGD","BK1589","BK4007","LU1894683264.USD","SG9999001176.SGD","LU2097828631.EUR","LU2097828805.USD","LU1969619763.USD","BK4568","LU0456855351.SGD","000963","LU0225771236.USD","LU2242644610.SGD","SG9999011175.SGD","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","BK4599","IE00BLSP4239.USD","LU2097828714.EUR","SG9999002224.SGD","LU0306806265.USD","LU1894683348.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","VKTX","IE0002270589.USD","SG9999013999.USD","LU0170899867.USD","LU1883839398.USD","RHHBY","LU1066051498.USD","LU0455707207.USD","LU0306807586.USD","BK1161","IE00BLSP4452.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2617687841","title":"CARsgen posts FY2025 net loss of CNY103 million, down 87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687841","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687841?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798697,"startTime":"0","endTime":"0","summary":"CARsgen reported FY 2025 revenue of CNY 125.7 million, mainly from zevor-cel, and FY 2025 gross profit of about CNY 80 million. The company posted a FY 2025 net loss of about CNY 103 million, down about 87% YoY. Cash and cash equivalents were about CNY 1.1 billion as of Dec. 31, 2025, and CARsgen said cash and cash equivalents at the end of 2026 are expected to be not less than CNY 1.0 billion. For 2025 commercialization, CARsgen said it received 218 confirmed zevor-cel orders from partner Huadong Medicine, and noted zevor-cel was included in China’s Commercial Health Insurance Innovative Drug Catalogue  in December 2025. On the pipeline, the company said China’s regulator accepted the NDA for satri-cel and granted Priority Review; CARsgen expects satri-cel to be approved in H1 2026 and initiate commercialization. CARsgen also highlighted progress in allogeneic CAR-T development and its lentiviral-based in vivo CAR T-cell CARvivo platform, and disclosed a Feb. 12, 2026 strategic cooper","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL11T47r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK1574","BK0187","BK0188","LU2328871848.SGD","LU1969619763.USD","BK0175","BK1587","BK0183","BK0209","BK1585","BK1161","BK0132","02171","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617876356","title":"Press Release: CARsgen Therapeutics Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617876356","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617876356?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798640,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.-- Cash and cash equivalents were around RMB1,123 million as of December 31,2025. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,000 million. The net loss for the year ended December 31,2025 was RMB103 million, representing a decrease of approximately 87%. compared to the year ended December 31, 2024. In light of operational. factors such as the changes in operating cash flow, we expect to have. -- During 2025, CARsgen has received a total of 218 confirmed orders of. zevor-cel from its commercialization partner Huadong Medicine. In. December 2025, zevor-cel has been included in China's Commercial Health. -- The Center for Drug Evaluation  of the National Medical Products.  and granted Priority Review for satri-cel. The results of satri-cel. confirmatory Phase II trial i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK4139","BK4195","BK4588","BK0196","R","000963","CAR","PFS","BK1161","BK1574","BK4539","BK1585","BK0132","LU1223083913.SGD","BK0183","BK4097","BK4211","BK4232","TM","LU1223082519.USD","BK0175","BK4017","BK4555","LENZ","LU1969619763.USD","02171","03160","BK1587","BK4099","BK4022","BK0209","BK4585","BK0187","CDE","BK4007","LU1223082196.USD","LU2328871848.SGD","BK4230","OS","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161853709","title":"Huadong Medicine Co.,Ltd. Announces Controlling Shareholder Releases 49 Million Shares from Pledge","url":"https://stock-news.laohu8.com/highlight/detail?id=1161853709","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161853709?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:21","pubTimestamp":1772796112,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. disclosed that its controlling shareholder, China Grand Enterprises (Group) Co., Ltd., has recently released a portion of its pledged shares. The number of shares released from pledge amounts to 49 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0188","000963","BK0132","LU1969619763.USD","BK0175","LU2328871848.SGD","BK0187","BK0183","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616313527","title":"Huadong Medicine Obtains Greenlight for Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616313527","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616313527?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:10","pubTimestamp":1772518246,"startTime":"0","endTime":"0","summary":"Huadong Medicine  subsidiary Zhejiang Doer Biologics obtained the approval of China's drug regulator to conduct clinical trials for DR30206 combined with chemotherapy to treat non-small cell lung cancer.DR30206 is designed to restore immune response while inhibiting tumor growth, according to a Wednesday filing with the Shenzhen bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000963","BK0183","BK0196","LU1969619763.USD","LU2328871848.SGD","BK0187","BK0209","BK0188","BK0132","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173704499","title":"Huadong Medicine's Subsidiary Gains Approval for Clinical Trial of DR30206 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1173704499","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173704499?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:01","pubTimestamp":1772449279,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) has announced that its subsidiary, Zhejiang Doer Biologics Co., Ltd., recently received a clinical trial approval notice from the National Medical Products...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0196","BK0187","BK0132","BK0209","BK0175","LU2328871848.SGD","BK0188","LU1969619763.USD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104849308","title":"Huadong Medicine Appeals to Supreme Court After Losing Initial Patent Lawsuit Against Jolly Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1104849308","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104849308?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:14","pubTimestamp":1772158459,"startTime":"0","endTime":"0","summary":"Following an unsuccessful initial ruling, Huadong Medicine Co.,Ltd. has proceeded with an appeal. On the evening of February 26, Zhejiang Jolly Pharmaceutical Co.,Ltd. announced that due to a patent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0077","BK0183","BK0187","BK0042","000963","BK0188","BK0239","BK0175","BK0132","300181","LU1969619763.USD","BK0209","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609344880","title":"Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609344880","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609344880?lang=en_us&edition=fundamental","pubTime":"2026-02-05 12:15","pubTimestamp":1770264933,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) unit, Zhejiang Doer Biologics, obtained approval from China's National Medical Products Administration for the clinical trial of DR10624 injection, according to a Shenz","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0183","BK0187","BK0188","000963","BK0175","BK0132","LU1969619763.USD","BK0209","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179334322","title":"Huadong Medicine Subsidiary's DR10624 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1179334322","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179334322?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:56","pubTimestamp":1770198974,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its subsidiary, Zhejiang Daoer Biotechnology Co., Ltd., has obtained a \"Drug Clinical Trial Approval Notice\" issued by the National Medical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","BK0209","BK0175","BK0196","LU1969619763.USD","BK0188","BK0183","BK0187","000963","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","stockEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0558},{"period":"3month","weight":-0.0754},{"period":"6month","weight":-0.1979},{"period":"1year","weight":-0.123},{"period":"ytd","weight":-0.1546}],"companyName":"华东医药股份有限公司","boardCode":"AI0052","perCapita":"20793股","boardName":"零售业","registeredCapital":"175373万元","compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"survey":"　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。","serverTime":1777796497739,"listedPrice":5.76,"stockholders":"84304人(较上一季度增加26.48%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction